These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12803732)

  • 1. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease.
    Karaca I; Ilkay E; Akbulut M; Yavuzkir M; Pekdemir M; Akbulut H; Arslan N
    Curr Med Res Opin; 2003; 19(3):187-91. PubMed ID: 12803732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
    Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
    Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin and pravastatin on serum C-reactive protein.
    Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Taylor AJ
    Am Heart J; 2003 Feb; 145(2):e8. PubMed ID: 12595863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
    Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ; Watson KE; Weiss RE; Fonarow GC
    Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
    Rifaie O; Zahran A; Nammas W
    Anadolu Kardiyol Derg; 2012 Mar; 12(2):90-6. PubMed ID: 22281786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
    Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of atorvastatin on C-reactive protein.
    Riesen WF; Engler H; Risch M; Korte W; Noseda G
    Eur Heart J; 2002 May; 23(10):794-9. PubMed ID: 12009719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
    Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.